DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083
DelMar Pharmaceuticals, Inc. (DMPI) (DelMar and the Company), a company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application number 13/817,096 entitled, "Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol."VAL-083 Demonstrates Promises a Potential Treatment for Non-Small Cell Lung Cancer
DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), a clinical-stage oncology company, today announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC) at the AACR’s New Horizons in Cancer Research: Harnessing Breakthroughs – Targeting Cures. The conference takes place October 9th to 12th in Pudong, Shanghai.Brain Cancer Patients May Have New Hope
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) is developing a new drug intended to treat various forms of cancer, including a recurrent form of Brian Cancer, glioblastoma multiforme. The DelMar treatment VAL-083 is in Phase l/ll trials and showing promising results.DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" “the company”) today announced the filing of June 30, 2014 fiscal year-end financial statements. The Company recently changed its fiscal year end to June 30th in order to facilitate an application to list its common stock on a national securities exchange in the timeliest manner possible.DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer
DelMar Pharmaceuticals, Inc.(OTCQB: DMPI) ("DelMar" “the company”) announced today a protocol amendment to allow for expanded dosing in its VAL-083 clinical trial had been filed with the U.S. Food and Drug Administration (FDA) and that a new cohort of a new 50mg/m2 has been opened at three clinical trial sites in the United States. The company also confirmed that gross proceeds of US$2.9 million have been raised through warrant exercise in two separate closings. These funds provide sufficient working capital to fund DelMar’s current operations, including its glioblastoma clinical trial, through at least December 2015.